Program
Pramipexole
Also written as “pramipexole”, “Pramipexole Dihydrochloride” and “Pramipexole Immediate Release”.
Its studies are mostly in Parkinson Disease · Restless Legs Syndrome · Tourette Syndrome · Depressive Disorder, Major · Obsessive-Compulsive Disorder, led by 6 companies.
Drug pagePramipexole: every studyMany companies study it; this page follows only the 43 they lead. All 81 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 360 open or running | phase 4since Sep 2, 2005 | Aug 22, 2005 | none ahead |
| Teva Pharmaceutical Industriesits history only | 30 open or running | phase 4since Nov 10, 2006 | Nov 10, 2006 | none ahead |
| Chase Therapeuticsits history only | 11 open or running | phase 2since Jul 5, 2018 | Jul 5, 2018 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since May 8, 2007 | May 8, 2007 | none ahead |
| Haisco Pharmaceutical Groupits history only | 10 open or running | phase 1since Apr 2, 2026 | Apr 2, 2026 | none ahead |
| Novartisits history only | 10 open or running | phase 4since Aug 23, 2012 | Aug 23, 2012 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Boehringer Ingelheim only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Aug 22, 2005.
- Nov 12, 20072 phase 3 studies in Parkinson DiseaseNCT00558025, NCT00560508
- Nov 14, 2007Phase 2 study in Tourette SyndromeNCT00558467 · 63 enrolled · United States, Germany
- Dec 19, 2007Phase 3 study in Parkinson DiseaseNCT00577460 · 391 enrolled · Austria, Czech Republic, Hungary and more
- Jan 15, 2008Phase 3 study in Parkinson DiseaseNCT00601523 · 511 enrolled · United States, Austria, Czech Republic and more
- Mar 27, 2008Phase 3 study in Restless Legs SyndromeNCT00654498 · 306 enrolled · China
- May 19, 2008Phase 3 study in Tourette SyndromeNCT00681863 · 45 enrolled · United States, Germany
- May 29, 2008Phase 2 study in FibromyalgiaNCT00689052 · 61 enrolled · United States
- Aug 30, 2010Phase 3 study in Parkinson DiseaseNCT01191944 · 475 enrolled · China
- Oct 1, 2010Phase 1 study in HealthyNCT01214109 · 24 enrolled · China
- Jun 20, 20142 phase 3 studies in Parkinson DiseaseNCT02172573, NCT02177357
- Sep 4, 2014Phase 4 study in Parkinson DiseaseNCT02233023 · 705 enrolled
- Oct 9, 20143 phase 1 studies in HealthyNCT02262546, NCT02261103, NCT02264132
- Apr 11, 2018Phase 4 study in Parkinson DiseaseNCT03521635 · 98 enrolled · China
- Jul 22, 2026Phase 1 study in HealthyNCT07727785 · 25 enrolled · Germany
TargetBeta
“D2-like dopamine receptor agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| rotigotinerule | UCB | phase 4 | 64 |
Studies
All 36 Boehringer Ingelheim leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07727785Healthy · Germany | 1 | Completed | Sep 10, 2026 | 25 |
| NCT03521635Parkinson Disease · China | 4 | Completed | Jan 7, 2020 | 98 |
| NCT02264132Healthy | 1 | Completed | Nov 2006 | 24 |
| NCT02262546Healthy | 1 | Completed | Oct 2007 | 60 |
| NCT02261103Healthy | 1 | Completed | Jul 2006 | 39 |
| NCT02233023Parkinson Disease | 4 | Completed | Jun 2000 | 705 |
| NCT02177357Parkinson Disease | 3 | Completed | Jan 2000 | 150 |
| NCT02172573Parkinson Disease | 3 | Completed | Jul 2000 | 315 |
| NCT01214109Healthy · China | 1 | Completed | Jan 2011 | 24 |
| NCT01191944Parkinson Disease · China | 3 | Completed | Jan 2012 | 475 |
| NCT00689052Fibromyalgia · United States | 2 | Terminated | Nov 2008 | 61 |
| NCT00681863Tourette Syndrome · United States, Germany | 3 | Terminated | Oct 2009 | 45 |
| NCT00654498Restless Legs Syndrome · China | 3 | Completed | Jun 2009 | 306 |
| NCT00601523Parkinson Disease · United States, Austria, Czech Republic and more | 3 | Completed | Jun 2010 | 511 |
| NCT00577460Parkinson Disease · Austria, Czech Republic, Hungary and more | 3 | Completed | Jun 2010 | 391 |
| NCT00560508Parkinson Disease · Japan | 3 | Completed | Nov 2009 | 112 |
| NCT00558467Tourette Syndrome · United States, Germany | 2 | Completed | Jun 2009 | 63 |
| NCT00558025Parkinson Disease · France, Germany, Netherlands | 3 | Completed | May 2008 | 156 |
| NCT00479401Parkinson Disease · United States, Argentina, Austria and more | 3 | Completed | Nov 2008 | 539 |
| NCT00472199Restless Legs Syndrome · Austria, Belgium, Finland and more | 4 | Completed | Jul 2008 | 331 |
| NCT00466167Parkinson Disease · Austria, Czech Republic, Hungary and more | 3 | Completed | Nov 2008 | 517 |
| NCT00402233Parkinson Disease · United States | 4 | Completed | Sep 2008 | 312 |
| NCT00390689Idiopathic Restless Legs Syndrome · Japan | 3 | Completed | Mar 2008 | 154 |
| NCT00375284Restless Legs Syndrome · United States | 4 | Completed | Jul 2007 | 404 |
| NCT00356096Restless Legs Syndrome · Finland, France, Germany and more | 4 | Completed | Jun 2007 | 404 |
| NCT00349531Restless Legs Syndrome · Denmark, Finland, Germany and more | 4 | Completed | May 2007 | 369 |
| NCT00321854Parkinson Disease · United States, Austria, Finland and more | 4 | Completed | Apr 2009 | 535 |
| NCT00297778Parkinson Disease · Austria, Finland, France and more | 4 | Completed | May 2008 | 296 |
| NCT00275457Restless Legs Syndrome · Austria, Germany, Netherlands and more | 3 | Completed | Apr 2004 | 346 |
| NCT00240409Parkinson Disease · China | 3 | Completed | Aug 2004 | 208 |
| NCT00239486Restless Legs Syndrome · Finland | 2 | Completed | Apr 2004 | 109 |
| NCT00152997Restless Legs Syndrome · Japan | 2 | Completed | Dec 2005 | 41 |
| NCT00152958Restless Legs Syndrome · Germany | 3 | Completed | Feb 2005 | 224 |
| NCT00144300Parkinson Disease · United States | 4 | Completed | Sep 2010 | 246 |
| NCT00144209Restless Legs Syndrome · Switzerland | 3 | Completed | Feb 2005 | 58 |
| NCT00133198Restless Legs Syndrome · United States | 3 | Completed | Feb 2005 | 345 |
How it is read
Names in the registry
- “Pramipexole”, 15 entries
- “pramipexole”, 5 entries
- “Pramipexole Dihydrochloride”, 4 entries
- “Pramipexole Immediate Release”, 2 entries
- “Pramipexole Extended Release”, 2 entries
Conditions, from the studies’ own filings
- Parkinson Disease, 19 studies
- Restless Legs Syndrome, 12 studies
- Tourette Syndrome, 2 studies
- Depressive Disorder, Major, 1 study
- Obsessive-Compulsive Disorder, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.